PKCδ serves as a potential biomarker and therapeutic target for microglia-mediated neuroinflammation in Alzheimer's disease

P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy

Passive immunotherapy for Alzheimer's disease

Minocycline protects against microgliopathy in a <i>Csf1r</i> haplo-insufficient mouse model of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)

Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies (vol 19, 259, 2022)

Gene therapy using human FMRP isoforms driven by the human FMR1 promoter rescues fragile X syndrome mouse deficits

Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies

Downregulating PTBP1 Fails to Convert Astrocytes into Hippocampal Neurons and to Alleviate Symptoms in Alzheimer's Mouse Models

A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer's disease

APOE interacts with ACE2 inhibiting SARS-CoV-2 cellular entry and inflammation in COVID-19 patients

LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions

Microglial lactate metabolism as a potential therapeutic target for Alzheimer's disease

USP25 inhibition ameliorates Alzheimer's pathology through the regulation of APP processing and A beta generation

Nuclear speckle specific hnRNP D-like prevents age- and AD-related cognitive decline by modulating RNA splicing

SNX14 deficiency-induced defective axonal mitochondrial transport in Purkinje cells underlies cerebellar ataxia and can be reversed by valproate

Trisomy 21-induced dysregulation of microglial homeostasis in Alzheimer's brains is mediated by USP25

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease